Why Are Insiders Buying Opko Health? $OPK

In the financial world, there are many reasons why corporate insiders would choose to sell their company’s stock, but only one reason why they would choose to buy.  Over the past decade, there has been a flood of empirical research – Lakonishok in 2001, Jeng and Metrick in 2003 – focused on determining the profitability of insider trading.

Opko Health Inc. (NYSE:OPK)

Interestingly enough, each study discovered a statistically significant relationship between insider purchases and abnormal returns, effectively throwing a wrench in the strong-form efficient market hypothesis.  When the dust settled, it was found that investors who mimic, or “monkey” insider buying behavior can beat the market by 6.4 percent per year, risk-adjusted.  Amidst seemingly never-ending Eurozone difficulties and plenty of headlines like this one floating around the blogosphere, any strategy that can consistently outperform the market should be welcomed with open arms.  So here’s a note to all insider monkeys out there: Opko Health (NYSE: OPK) has seen a rash of purchases lately, which are detailed below for your viewing pleasure.

Dr. Phillip Frost: With a name that sounds like he suits up as Mr. Freeze in the twilight hours of Gotham City, Dr. Frost has been quite the bull lately.  As the CEO and Chairman of the drug and medical device company, Frost is theoretically the best insider to follow, not to mention that his current net worth ($2.3B) exceeds Opko’s entire market value ($1.4B).  Since May, he has bought 2.23 million shares of OPK for a total value north of $10 million, increasing his total ownership of Opko to 37.3 percent.

Over this same time, the stock’s value has remained relatively flat, though the company has announced a key U.S. patent allowance of its “Flow Control in Microfluidic Systems” application.  While this sounds like medical gobbledygook, it essentially gives the company a way have a larger foothold in the point-of-care diagnostics market.  Anytime you have your cholesterol checked or glucose levels monitored, a POC device is most likely used (here’s a good way to visualize this technology).  Now, it’s estimated that the total size of the POC market will be worth $16.5 billion by 2016, up from $13.8 billion today.  So, it may be the combination of this macroeconomic tailwind with Opko’s newfound patent advantage that explains Frost’s bullishness.

Dr. Richard Lerner: Aside from the CEO, company director Richard Lerner has also bought shares of OPK over the past couple months, adding 50,000 shares at an average price of $4.60 each.  While this amount is much smaller than those of his superior, it does represent a larger portion of Lerner’s portfolio, as these transactions nearly doubled his total holdings of the stock.  Interestingly, Lerner has served as the President of the Scripps Research Institute, a nonprofit biomedical research institute with links to POC explorations.  If something big were on Opko’s horizon, Lerner would clearly have the expertise to understand the potential benefits of such a possibility.

From an investment standpoint, Opko has been a dud in 2012, losing 5.9 percent of its value.  The company has reported negative earnings in each of the past five years, though they are nearing profitability.  After having an EPS of -$0.13 in 2009, and -$0.08 in 2010, OPK almost broke even last year, reporting an earnings loss of 1 cent a share.  By the end of this year, the Street is still expecting a loss of 10 cents a share, so much is riding on the company’s next earnings release the second week of August.

Bulls will point to Opko’s $8.8 million in revenues in the first quarter of 2012, which was up 51.5 percent year-over-year, but this did underwhelm analyst expectations, who were forecasting a top line of $9.1 million.  Negative earnings makes traditional P/E analysis unusable, but it is notable that the stock is currently trading at a Price-to-Book ratio (8.8X) that is way above the industry average (2.3X), and competitors like Medtronic (NYSE: MDT) at 2.3X, Stryker Corp (NYSE: SYK) at 2.5X, and Waters Corp (NYSE: WAT) at 5.2X.  If Opko does warrant this high valuation, its POC patent may provide the dollars.  WealthLift’s Sentiment Index rates OPK as a hold, as users are mixed on what the future may hold for this drug and medical device company.  To read up on other trading ideas in this uncertain market environment, visit WealthLift INSIDER today.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Most Overrated Movies Of All Time by Out-of-Touch Critics

Top 6 Least Expensive Cruise Destinations For 2015 that Will Take You to Paradise

10 States with Lowest Substance Abuse Rates in America

The 14 Most Watched TV Finales Ever

The 10 Best Selling Role Playing Games of All Time for PC

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!